- Home
- XCUR vs CTSO Comparison
XCUR vs CTSO Comparison
Compare XCUR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- CTSO
- Stock Information
- Founded
- XCUR 2011
- CTSO 1997
- Country
- XCUR United States
- CTSO United States
- Employees
- XCUR N/A
- CTSO N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- XCUR Health Care
- CTSO Health Care
- Exchange
- XCUR Nasdaq
- CTSO Nasdaq
- Market Cap
- XCUR 74.1M
- CTSO 68.2M
- IPO Year
- XCUR N/A
- CTSO N/A
- Fundamental
- Price
- XCUR $11.06
- CTSO $0.87
- Analyst Decision
- XCUR
- CTSO Strong Buy
- Analyst Count
- XCUR 0
- CTSO 3
- Target Price
- XCUR N/A
- CTSO $4.67
- AVG Volume (30 Days)
- XCUR 31.7K
- CTSO 138.6K
- Earning Date
- XCUR 06-16-2025
- CTSO 05-14-2025
- Dividend Yield
- XCUR N/A
- CTSO N/A
- EPS Growth
- XCUR N/A
- CTSO N/A
- EPS
- XCUR N/A
- CTSO N/A
- Revenue
- XCUR $500,000.00
- CTSO $35,594,520.00
- Revenue This Year
- XCUR N/A
- CTSO $18.72
- Revenue Next Year
- XCUR N/A
- CTSO $19.75
- P/E Ratio
- XCUR N/A
- CTSO N/A
- Revenue Growth
- XCUR N/A
- CTSO 14.51
- 52 Week Low
- XCUR $1.44
- CTSO $0.70
- 52 Week High
- XCUR $36.00
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- XCUR 49.48
- CTSO 34.05
- Support Level
- XCUR $9.81
- CTSO $0.87
- Resistance Level
- XCUR $11.60
- CTSO $1.16
- Average True Range (ATR)
- XCUR 0.91
- CTSO 0.06
- MACD
- XCUR 0.06
- CTSO -0.02
- Stochastic Oscillator
- XCUR 43.98
- CTSO 0.34
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.